- The fourth quarter of 2025 witnessed an unprecedented surge in ANDA patent litigation cases, with over 80 new lawsuits filed as generic manufacturers challenged patents protecting major pharmaceutical products. - High-value drug patents faced multiple challenges, including Bayer's Kerendia (finerenone) targeted by at least 10 generic companies and AbbVie's Qulipta (atogepant) facing litigation from multiple manufacturers. - Settlement activity remained robust with over 50 cases resolved, often resulting in injunctions preventing generic entry until patent expiration while allowing FDA approval processes to continue.

Jan 31, 2026

返回机构列表

Oyster Point Pharma, Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（11）

A Study Evaluating the Safety of the Nasal Pump

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

药物批准

按机构分类的批准

近期批准

资讯

Major Pharmaceutical Patent Litigation Wave Intensifies in Q4 2025 as Generic Manufacturers Challenge Key Drug Patents